BridgeMD
New treatment option for Atypical Alzheimer's Disease
Official title Molecular and Structural Imaging in Alzheimer's Disease: A Longitudinal Study
ClinicalTrials.gov ID: NCT02740634
What this study is testing
What is F-18 AV 1451?
F-18 AV 1451 is an investigational medicine, being studied as a potential treatment for atypical alzheimer's disease.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This is a neuroimaging study designed to learn more about amyloid and tau burden in the brain of patients with typical and atypical Alzheimer's Disease and how burden may change over a one year period.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 21 to 80
You may be able to join if
- Over the age of 21
- Must have an informant who will be able to provide independent evaluation of functioning
- English is primary language
- All people must have insidious onset, report progression of their symptoms, and meet current clinical diagnostic criteria for typical amnestic AD or...
- All people with Logopenic Aphasia (LPA) must present with early and dominant impairments in language
You likely can't join if
- If you have had a stroke or tumor that could explain your symptoms
- people that present with early episodic memory impairment or meet clinical criteria for mild cognitive impairment will not be recruited into the study
- people that meet specific criteria for another neurodegenerative disorder, including behavioral variant frontotemporal dementia, semantic dementia...
- people will be excluded if they have poor vision (20/400)
- Women that are pregnant or post-partum and breast-feeding will be excluded
- people will be excluded from the study if they are unable to undergo the tau-PET scan due to a prolonged QT interval on ECG, or if they have any of...
See the full eligibility criteria
- Over the age of 21
- Must have an informant who will be able to provide independent evaluation of functioning
- English is primary language
- All people must have insidious onset, report progression of their symptoms, and meet current clinical diagnostic criteria for typical amnestic AD or an atypical AD syndrome such as Logopenic Aphasia (LPA) or Posterior...
- All people with Logopenic Aphasia (LPA) must present with early and dominant impairments in language
- All people with typical amnestic AD must have relative preservation of episodic memory compared to impairment in the non-episodic memory domain
- If you have had a stroke or tumor that could explain your symptoms
- people that present with early episodic memory impairment or meet clinical criteria for mild cognitive impairment will not be recruited into the study
- people that meet specific criteria for another neurodegenerative disorder, including behavioral variant frontotemporal dementia, semantic dementia, primary progressive apraxia of speech, probable corticobasal syndrome...
- people will be excluded if they have poor vision (20/400)
- Women that are pregnant or post-partum and breast-feeding will be excluded
- people will be excluded from the study if they are unable to undergo the tau-PET scan due to a prolonged QT interval on ECG, or if they have any of the following genetic conditions which can increase the chance of...
- people will also be excluded if MRI is contraindicated (metal in head, cardiac pace maker, e.t.c.), if there is severe claustrophobia, if there are conditions that may confound brain imaging studies (e.g. structural...
The study team makes the final eligibility decision.
Where it's taking place
- Rochester, Minnesota, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 21 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Rochester, Minnesota, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.